Literature DB >> 30105522

Hepatocellular Carcinoma with Orbital Metastasis: a Unique Multidisciplinary Case Report.

Matthew Michael Sochat1, Jinhua Piao2, Nishant Poddar3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30105522     DOI： 10.1007/s12029-018-0159-3

Source DB:  PubMed          Journal:  J Gastrointest Cancer


× No keyword cloud information.
  16 in total

1.  International trends in liver cancer incidence, overall and by histologic subtype, 1978-2007.

Authors:  Jessica L Petrick; Megan Braunlin; Mathieu Laversanne; Patricia C Valery; Freddie Bray; Katherine A McGlynn
Journal:  Int J Cancer       Date:  2016-06-28       Impact factor: 7.396

Review 2.  Orbital metastasis from hepatocellular carcinoma.

Authors:  Roshmi Gupta; Santosh G Honavar; Geeta K Vemuganti
Journal:  Surv Ophthalmol       Date:  2005 Sep-Oct       Impact factor: 6.048

3.  Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: a prospective, multicenter study.

Authors:  Eiichi Ogawa; Norihiro Furusyo; Eiji Kajiwara; Kazuhiro Takahashi; Hideyuki Nomura; Toshihiro Maruyama; Yuichi Tanabe; Takeaki Satoh; Makoto Nakamuta; Kazuhiro Kotoh; Koichi Azuma; Kazufumi Dohmen; Shinji Shimoda; Jun Hayashi
Journal:  J Hepatol       Date:  2012-10-23       Impact factor: 25.083

4.  Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.

Authors:  Anthony B El-Khoueiry; Bruno Sangro; Thomas Yau; Todd S Crocenzi; Masatoshi Kudo; Chiun Hsu; Tae-You Kim; Su-Pin Choo; Jörg Trojan; Theodore H Welling; Tim Meyer; Yoon-Koo Kang; Winnie Yeo; Akhil Chopra; Jeffrey Anderson; Christine Dela Cruz; Lixin Lang; Jaclyn Neely; Hao Tang; Homa B Dastani; Ignacio Melero
Journal:  Lancet       Date:  2017-04-20       Impact factor: 79.321

Review 5.  The clinical management of hepatocellular carcinoma worldwide: A concise review and comparison of current guidelines from 2001 to 2017.

Authors:  Peipei Song; Yulong Cai; Haowen Tang; Chuan Li; Jiwei Huang
Journal:  Biosci Trends       Date:  2017       Impact factor: 2.400

6.  Orbital metastasis from hepatocellular carcinoma: report of 6 cases.

Authors:  Mohammed A Eldesouky; Molham A Elbakary; Osama E Shalaby; Mohamed M Shareef
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2014 Jul-Aug       Impact factor: 1.746

7.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.

Authors:  Ann-Lii Cheng; Yoon-Koo Kang; Zhendong Chen; Chao-Jung Tsao; Shukui Qin; Jun Suk Kim; Rongcheng Luo; Jifeng Feng; Shenglong Ye; Tsai-Sheng Yang; Jianming Xu; Yan Sun; Houjie Liang; Jiwei Liu; Jiejun Wang; Won Young Tak; Hongming Pan; Karin Burock; Jessie Zou; Dimitris Voliotis; Zhongzhen Guan
Journal:  Lancet Oncol       Date:  2008-12-16       Impact factor: 41.316

8.  Population attributable fractions of risk factors for hepatocellular carcinoma in the United States.

Authors:  Oxana V Makarova-Rusher; Sean F Altekruse; Tim S McNeel; Susanna Ulahannan; Austin G Duffy; Barry I Graubard; Tim F Greten; Katherine A McGlynn
Journal:  Cancer       Date:  2016-03-21       Impact factor: 6.860

9.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

10.  Randomized controlled trial of screening for hepatocellular carcinoma.

Authors:  Bo-Heng Zhang; Bing-Hui Yang; Zhao-You Tang
Journal:  J Cancer Res Clin Oncol       Date:  2004-07       Impact factor: 4.553
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.